Humoral deficiencies represent a broad group of disorders. The aim of the study was to compare the levels of antibodies against pneumococcal capsular polysaccharides (anti-PCP) and natural anti-galactosyl (anti-Gal) antibodies in (1) patients with chronic lymphocytic leukaemia (CLL), (2) patients with common variable immunodeficiency (CVID), and (3) a healthy population and to explore their diagnostic and prognostic potential. Serum immunoglobulin levels and levels of anti-Gal IgG, IgA, and IgM and anti-PCP IgG and IgG2 were determined in 59 CLL patients, 30 CVID patients, and 67 healthy controls. Levels of IgG, IgA, IgM, anti-Gal IgA, anti-Gal IgM, and anti-PCP IgA were lower in CLL and CVID patients than in healthy controls (p value for all parameters < 0.0001). Decrease in the levels of IgA, IgM, anti-Gal IgA, and anti-PCP IgA was less pronounced in the CLL group than in the CVID group. IgA decline, anti-Gal IgA, anti-PCP IgA, and anti-PCP IgG2 were negatively correlated with CLL stage. We devise the evaluation of anti-Gal antibodies to be a routine test in humoral immunodeficiency diagnostics, even in cases of immunoglobulin substitution therapy. Significant reductions, mainly in anti-Gal IgA, IgM, and anti-PCP IgA levels, may have prognostic importance in CLL patients.

4th Department of Internal Medicine Haematology Faculty of Medicine Charles University and University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Clinical Immunology and Allergy Faculty of Medicine Masaryk University St Anne's University Hospital Brno Czech Republic

Department of Mathematics Faculty of Science University of Hradec Kralove Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology Faculty of Medicine in Hradec Kralove Charles University and University Hospital Hradec Kralove Hradec Kralove Czech Republic

RECETOX Faculty of Science Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Scarfo L., Ferreri A. J., Ghia P. Chronic lymphocytic leukaemia. Critical Reviews in Oncology/Hematology. 2016;104:169–182. doi: 10.1016/j.critrevonc.2016.06.003. PubMed DOI

Van Bockstaele F., Verhasselt B., Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Reviews. 2009;23(1):25–47. doi: 10.1016/j.blre.2008.05.003. PubMed DOI

Dasanu C. A., Alexandrescu D. T. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. Medscape General Medicine. 2007;9(4):p. 35. PubMed PMC

Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leukemia & Lymphoma. 1994;13(3-4):203–214. doi: 10.3109/10428199409056283. PubMed DOI

Oscier D., Dearden C., Eren E., et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology. 2012;159(5):541–564. doi: 10.1111/bjh.12067. PubMed DOI

Hamblin A. D., Hamblin T. J. The immunodeficiency of chronic lymphocytic leukaemia. British Medical Bulletin. 2008;87:49–62. doi: 10.1093/bmb/ldn034. PubMed DOI

Ravandi F., O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy. 2006;55(2):197–209. doi: 10.1007/s00262-005-0015-8. PubMed DOI PMC

Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology. American Society of Hematology. Education Program. 2008;2008:450–456. doi: 10.1182/asheducation-2008.1.450. PubMed DOI

Friman V., Winqvist O., Blimark C., Langerbeins P., Chapel H., Dhalla F. Secondary immunodeficiency in lymphoproliferative malignancies. Hematological Oncology. 2016;34(3):121–132. doi: 10.1002/hon.2323. PubMed DOI

Sanchez-Ramon S., Dhalla F., Chapel H. Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Frontiers in Immunology. 2016;7:p. 317. doi: 10.3389/fimmu.2016.00317. PubMed DOI PMC

Jolles S., Chapel H., Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clinical and Experimental Immunology. 2017;188(3):333–341. doi: 10.1111/cei.12915. PubMed DOI PMC

Bonilla F. A., Barlan I., Chapel H., et al. International Consensus Document (ICON): common variable immunodeficiency disorders. The Journal of Allergy and Clinical Immunology. In Practice. 2016;4(1):38–59. doi: 10.1016/j.jaip.2015.07.025. PubMed DOI PMC

Resnick E. S., Moshier E. L., Godbold J. H., Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650–1657. doi: 10.1182/blood-2011-09-377945. PubMed DOI PMC

Gathmann B., Mahlaoui N., CEREDIH, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. The Journal of Allergy and Clinical Immunology. 2014;134(1):116–126. doi: 10.1016/j.jaci.2013.12.1077. PubMed DOI

Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology. 2013;140(1):1–11. doi: 10.1111/imm.12110. PubMed DOI PMC

Saleh H., Embry S., Nauli A., Atyia S., Krishnaswamy G. Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. Clinical and Molecular Allergy. 2012;10(1):p. 5. doi: 10.1186/1476-7961-10-5. PubMed DOI PMC

Chung C. H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. The New England Journal of Medicine. 2008;358(11):1109–1117. doi: 10.1056/NEJMoa074943. PubMed DOI PMC

Hamanova M., Chmelikova M., Nentwich I., Thon V., Lokaj J. Anti-Gal IgM, IgA and IgG natural antibodies in childhood. Immunology Letters. 2015;164(1):40–43. doi: 10.1016/j.imlet.2015.02.001. PubMed DOI

Bernth-Jensen J. M., Moller B. K., Jensenius J. C., Thiel S. Biological variation of anti-alpha Gal-antibodies studied by a novel time-resolved immunofluorometric assay. Journal of Immunological Methods. 2011;373(1-2):26–35. doi: 10.1016/j.jim.2011.07.017. PubMed DOI

Conley M. E., Notarangelo L. D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) Clinical Immunology. 1999;93(3):190–197. doi: 10.1006/clim.1999.4799. PubMed DOI

Parikh S. A., Leis J. F., Chaffee K. G., et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121(17):2883–2891. doi: 10.1002/cncr.29438. PubMed DOI PMC

Visentin A., Compagno N., Cinetto F., et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100(12):e515–e518. doi: 10.3324/haematol.2015.126763. PubMed DOI PMC

Griffiths H., Lea J., Bunch C., Lee M., Chapel H. Predictors of infection in chronic lymphocytic leukaemia (CLL) Clinical and Experimental Immunology. 1992;89(3):374–377. doi: 10.1111/j.1365-2249.1992.tb06965.x. PubMed DOI PMC

Ben-Bassat I., Many A., Modan M., Peretz C., Ramot B. Serum immunoglobulins in chronic lymphocytic leukemia. The American Journal of the Medical Sciences. 1979;278(1):4–9. doi: 10.1097/00000441-197907000-00001. PubMed DOI

Morrison V. A. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Practice & Research. Clinical Haematology. 2010;23:145–153. doi: 10.1016/j.beha.2009.12.004. PubMed DOI

Andersen M. A., Vojdeman F. J., Andersen M. K., et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leukemia & Lymphoma. 2016;57(7):1592–1599. doi: 10.3109/10428194.2016.1142082. PubMed DOI

Shvidel L., Tadmor T., Braester A., et al. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL study group. European Journal of Haematology. 2014;93(1):29–33. doi: 10.1111/ejh.12290. PubMed DOI

Pasiarski M., Rolinski J., Grywalska E., et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients – preliminary report. PLoS One. 2014;9(12, article e114966) doi: 10.1371/journal.pone.0114966. PubMed DOI PMC

Rozman C., Montserrat E., Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988;61(2):279–283. PubMed

Wadhwa P. D., Morrison V. A. Infectious complications of chronic lymphocytic leukemia. Seminars in Oncology. 2006;33:240–249. PubMed

Quinti I., Soresina A., Guerra A., et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. Journal of Clinical Immunology. 2011;31(3):315–322. doi: 10.1007/s10875-011-9511-0. PubMed DOI

Cavaliere F. M., Milito C., Martini H., et al. Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency. Journal of Clinical Immunology. 2013;33(4):838–846. doi: 10.1007/s10875-012-9856-z. PubMed DOI

Freeman J. A., Crassini K. R., Best O. G., et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia & Lymphoma. 2013;54(1):99–104. doi: 10.3109/10428194.2012.706285. PubMed DOI

Svensson T., Hoglund M., Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scandinavian Journal of Infectious Diseases. 2013;45:537–542. doi: 10.3109/00365548.2013.769279. PubMed DOI

Nosari A. Infectious complications in chronic lymphocytic leukemia. Mediterranean Journal of Hematology and Infectious Diseases. 2012;4(1, article e2012070) doi: 10.4084/MJHID.2012.070. PubMed DOI PMC

Sinisalo M., Aittoniemi J., Oivanen P., Käyhty H., Olander R. M., Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 2001;114(1):107–110. doi: 10.1046/j.1365-2141.2001.02882.x. PubMed DOI

Hartkamp A., Mulder A. H., Rijkers G. T., van Velzen-Blad H., Biesma D. H. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19(13-14):1671–1677. doi: 10.1016/s0264-410x(00)00409-6. PubMed DOI

Sinisalo M., Vilpo J., Itälä M., Väkeväinen M., Taurio J., Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26(1):82–87. doi: 10.1016/j.vaccine.2007.10.053. PubMed DOI

Parker W., Lundberg-Swanson K., Holzknecht Z. E., et al. Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies. Human Immunology. 1996;45(2):94–104. doi: 10.1016/0198-8859(95)00216-2. PubMed DOI

Chovancova Z., Vlkova M., Litzman J., Litzman J., Lokaj J., Thon V. Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination. Vaccine. 2011;29(24):4142–4150. PubMed